Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Are cardiovascular diseases a subspeciality of clinical immunology?

× No keyword cloud information.

29 in total

Review 1. Systemic lupus erythematosus: a model for atherogenesis?

Authors: S Manzi
Journal: Rheumatology (Oxford) Date: 2000-04 Impact factor: 7.580

Review 2. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.

Authors: F M Sacks
Journal: Am J Cardiol Date: 2001-12-20 Impact factor: 2.778

Review 3. Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome.

Authors: J George; D Haratz; Y Shoenfeld
Journal: Rheum Dis Clin North Am Date: 2001-08 Impact factor: 2.670

Review 4. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.

Authors: K K Koh
Journal: Cardiovasc Res Date: 2000-09 Impact factor: 10.787

Review 5. Are there potential non-lipid-lowering uses of statins?

Authors: D C Wheeler
Journal: Drugs Date: 1998-10 Impact factor: 9.546

6. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors: B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal: N Engl J Med Date: 1990-07-26 Impact factor: 91.245

7. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro.

Authors: S Kapadia; G Torre-Amione; T Yokoyama; D L Mann
Journal: Am J Physiol Date: 1995-02

8. CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes.

Authors: J K Damås; L Gullestad; T Ueland; N O Solum; S Simonsen; S S Frøland; P Aukrust
Journal: Cardiovasc Res Date: 2000-01-14 Impact factor: 10.787

9. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Authors: Y Y Li; Y Q Feng; T Kadokami; C F McTiernan; R Draviam; S C Watkins; A M Feldman
Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205

10. Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors: M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal: Am J Med Date: 1992-11 Impact factor: 4.965